ABOUT THE GUEST: Rahi Sarbaziha, MD is a physician in Beverly Hills, California whose practice focuses on regenerative aesthetics, hormone therapies, peptides, and interventions that support vitality, tissue repair, and overall wellness
Where it stumbles is cost clarity
Owing to their unique advantages in high solubility and stability, safety profile, tumor-targeting ability, and suitability as drug carriers, LAAM GSH-CQDs have the potential for translation into clinical applications for tumor-targeted imaging and drug delivery
Cancers 2(2):12881311
Wegovy cardiovascular risk reduction In March 2024, the FDA approved Wegovy for reducing the risk of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) in adults with established cardiovascular disease and overweight or obesity
A prospective randomized, double-blind, placebo-controlled, doseresponse relationship study to investigate efficacy of fructo-oligosaccharides (FOS) on human gut micromicrobiota